MGMT and central nervous system cancer: In grade III and IV gliomas, the frequency of MGMT methylation (53% and 34%, 90respectively) and IDH mutations (88% and 32%, respectively) reported in our study was similar to the previously reported incidence of biomarkers in high-grade gliomas (29, 30).